Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.

Sean WhartonPeter YinMelonie BurrowsErrol GouldJessica BlavignacRebecca A G ChristensenElham KamranFernando CamachoMaxime Barakat

Published in: International journal of obesity (2005) (2021)

NB appears to be effective in reducing weight in patients with T2DM and obesity/overweight who are taking DPP-4ihibitors or GLP-1RA. The SAE rates in all arms of this analysis were lower than have been reported in other cardiovascular outcome trials in type 2 diabetes.

Keyphrases

weight loss
type diabetes
weight gain
glycemic control
insulin resistance
physical activity
rheumatoid arthritis
metabolic syndrome
body mass index
study protocol
clinical trial
cardiovascular disease
phase ii
adipose tissue
ankylosing spondylitis
interstitial lung disease
systemic lupus erythematosus
data analysis